Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Apr 27, 2015
Last Price Change Open Day High 52-Week High
100.07
4.53  down   (4.331%) 105.00 105.42 118.95
Volume Previous Close Day Low 52-Week Low
794,000 104.60 98.00 12.76

View all »   RSSRecent Releases

Apr 7, 2015
Esperion Therapeutics to Present at 14th Annual Needham Healthcare Conference

Mar 24, 2015
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock